MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
CLRB Cellectar BioSciences
- 0.2350
- -0.0030-1.26%
Close Dec 20 16:00 ET
- 0.2380
- +0.0030+1.28%
Post 19:59 ET
9.70MMarket Cap-0.17P/E (TTM)
0.2495High0.2300Low2.19MVolume0.2400Open0.2380Pre Close520.67KTurnover6.42%Turnover RatioLossP/E (Static)41.27MShares4.450052wk High6.18P/B8.03MFloat Cap0.224052wk Low--Dividend TTM34.17MShs Float13678193.1609Historical High--Div YieldTTM8.19%Amplitude0.2240Historical Low0.2370Avg Price1Lot Size
About Cellectar BioSciences Company
Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124 which could detect tumors and metastases in a broad range of cancers and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
Company Profile
SymbolCLRB
Company NameCellectar BioSciences
Listing DateAug 15, 2014
Founded1996
CEOMr. James V. Caruso
MarketNASDAQ
Employees20
Fiscal Year Ends12-31
Address100 Campus Drive
CityFlorham Park
ProvinceNew Jersey
CountryUnited States of America
Zip Code07932
Phone1-608-441-8120
Websitehttp://www.cellectar.com
Company Executives
- Name
- Position
- Salary
- James V. Caruso
- Director, Chief Executive Officer and President
- 1.97M
- Shane Lea
- Chief Commercial Officer
- --
- Jarrod Longcor
- Chief Operating Officer
- 1.36M
- Chad J. Kolean
- Principal Accounting Officer, Vice President, Secretary and Chief Financial Officer
- 1.11M
- Andrei Shustov
- Senior Vice President, Medical
- --
- Douglas J Swirsky
- Chairman of the Board
- 109.88K
- Frederick W. Driscoll
- Independent Director
- 93.25K
- John P. Neis
- Independent Director
- 93.25K
- Dr. Stefan D. Loren, PhD
- Independent Director
- 93.25K
- Dr. Asher Chanan-Khan, M.B.B.S.,M.D.
- Independent Director
- 48.25K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.